Short-course chemotherapy for tuberculosis in children

Area of Science:

• Pediatric Infectious Diseases
• Pulmonary Medicine
• Pharmacology

Background:

• Tuberculosis (TB) treatment in children requires effective and safe regimens.
• Short-course chemotherapy was introduced for adult pulmonary TB in 1976.
• Pediatric TB treatment protocols needed evaluation for efficacy and safety.

Purpose of the Study:

• To evaluate the efficacy and safety of a short-course, twice-weekly chemotherapy regimen for treating tuberculosis in children.
• To assess the treatment outcomes and drug toxicity in pediatric patients with pulmonary and extrapulmonary TB.

Main Methods:

• A cohort of 50 children (4 months to 15 years) with tuberculosis received daily rifampin and isoniazid for one month, followed by twice-weekly doses for eight months.
• Diagnosis was based on purified protein derivative (PPD) skin testing, chest radiography, and clinical findings.
• Treatment outcomes, including symptom resolution and radiographic clearing, were monitored.

Main Results:

• Excellent treatment results were observed, with symptoms clearing in 1-2 months.
• Pulmonary infiltrates resolved in most cases by 10 months; hilar adenopathy took longer.
• Drug toxicity was minimal, with only one instance of vomiting attributed to rifampin.

Conclusions:

• Short-course chemotherapy with rifampin and isoniazid is a safe, effective, and well-tolerated treatment for childhood tuberculosis.
• The regimen's simplicity and short duration facilitate adherence and administration, especially in socially disadvantaged families.
• This approach offers a practical solution for managing pediatric TB, ensuring better patient cooperation and outcomes.